[ALXN] Alexion Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 28.04 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 127.19 Change: 1.34 (1.06%)
Ext. hours: Change: 0 (0%)

chart ALXN

Refresh chart

Strongest Trends Summary For ALXN

ALXN is in the medium-term down -17% below S&P in 6 months. In the long-term up 2522% in 25 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is

Fundamental Ratios
Shares Outstanding224.02 M EPS3.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 17.14% Sales Growth - Q/Q0.14% P/E37.13
P/E To EPS Growth P/S12.36 P/BV7.97 Price/Cash Per Share14.56
Price/Free Cash Flow55.69 ROA13.34% ROE16.74% ROI15.36%
Current Ratio4.92 Quick Ratio4.61 Long Term Debt/Equity0.05 Debt Ratio0.17
Gross Margin90.72% Operating Margin33.65% Net Profit Margin25.97% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.07 M Cash From Investing Activities-48.42 M Cash From Operating Activities23.03 M Gross Profit584.2 M
Net Profit170.22 M Operating Profit181.08 M Total Assets13.17 B Total Current Assets2.53 B
Total Current Liabilities769.17 M Total Debt3.5 B Total Liabilities4.61 B Total Revenue636.21 M
Technical Data
High 52 week141.3 Low 52 week93.94 Last close130.9 Last change-0.38%
RSI41.11 Average true range3.76 Beta1.14 Volume2.37 M
Simple moving average 20 days-1.22% Simple moving average 50 days-2.32% Simple moving average 200 days5.77%
Performance Data
Performance Week-0.6% Performance Month3.96% Performance Quart1.14% Performance Half10.45%
Performance Year9.39% Performance Year-to-date34.45% Volatility daily1.92% Volatility weekly4.28%
Volatility monthly8.78% Volatility yearly30.41% Relative Volume244.27% Average Volume1.33 M
New High New Low

News

2019-09-13 11:14:03 | Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

2019-09-13 09:40:01 | ALXN or CBM: Which Is the Better Value Stock Right Now?

2019-09-12 06:29:10 | Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks

2019-09-11 10:49:02 | Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus

2019-09-11 10:23:43 | 3 Hot Biotechs with High Upside Potential

2019-09-10 11:39:03 | Alexion ALXN In-licenses Amyloidosis Candidate In Japan

2019-09-09 10:10:02 | Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group

2019-09-09 09:31:01 | Has Alexion Pharmaceuticals ALXN Outpaced Other Medical Stocks This Year?

2019-09-09 07:30:00 | Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis ATTR Investigational Medicine

2019-09-06 16:48:53 | Bad News Keeps Piling Up For Alexion's Soliris — But Shares Just Rallied

2019-09-06 08:45:12 | 3 Reasons Growth Investors Will Love Alexion ALXN

2019-09-05 10:08:00 | Here's Why Alexion Pharmaceuticals Dropped 11% in August

2019-09-05 08:05:12 | 5 Price-to-Book Value Picks for September

2019-09-04 06:30:00 | Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

2019-08-31 09:35:23 | An Intrinsic Calculation For Alexion Pharmaceuticals, Inc. NASDAQ:ALXN Suggests It's 41% Undervalued

2019-08-30 16:35:00 | Why American Outdoor Brands, Innovative Industrial Properties, and Alexion Pharmaceuticals Slumped Today

2019-08-30 16:33:35 | How Amgen Could Take A Hammer To Sales Of Alexion's Biggest Drug

2019-08-30 12:50:31 | Options Pop on Alexion Stock Amid Patent Questions

2019-08-30 11:33:27 | Amgen drug patent challenge slices $2B off Alexion's market cap

2019-08-29 09:16:01 | Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court

2019-08-28 13:19:05 | Top Analyst Reports for Costco, PayPal & NextEra

2019-08-28 10:34:02 | Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More

2019-08-28 08:30:00 | Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

2019-08-28 06:30:00 | Alexion to Present at the 14th Annual Citi Biotech Conference

2019-08-28 06:28:10 | Alexion Wins EC Nod for Soliris in Nervous System Disorder

2019-08-27 08:58:12 | Alexion ALXN Down 3.2% After Amgen Buys Otezla From Celgene

2019-08-27 08:30:00 | European Commission Approves SOLIRIS® eculizumab For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder NMOSD

2019-08-26 09:30:01 | ALXN vs. CBM: Which Stock Is the Better Value Option?

2019-08-26 08:28:12 | Gilead & Galapagos Close Research & Development Agreement

2019-08-26 08:02:00 | Alexion Shares Decline in Wake of Amgen's Deal for Otezla

2019-08-25 11:31:00 | Should Amgen Finally Buy Alexion Pharmaceuticals?

2019-08-24 07:29:00 | 3 Reasons Why Amgen Could Actually Acquire Alexion

2019-08-23 16:10:39 | Why Alexion Makes Sense As A Target, But Amgen Doesn't As A Buyer

2019-08-23 15:26:18 | Amgen’s Alexion Acquisition: Does It Make Sense?

2019-08-23 09:31:01 | Why Is Alexion ALXN Up 4.6% Since Last Earnings Report?

2019-08-23 09:15:01 | Alexion Pharmaceuticals ALXN Jumps: Stock Rises 7.5%

2019-08-23 06:00:00 | A Pair of Rare Disease Biotech Concerns Worth a Good Look

2019-08-22 16:08:36 | Biotech Giant Amgen Could Be Nearing A Massive Takeover: Report

2019-08-22 13:11:00 | Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid

2019-08-22 12:01:04 | MyoKardia Begins Dosing in Phase I Study on Heart Candidate

2019-08-21 11:08:03 | NuCana Stops Patient Enrollment in Pancreatic Cancer Study

2019-08-21 08:45:12 | Alexion ALXN is an Incredible Growth Stock: 3 Reasons Why

2019-08-20 17:14:09 | Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100

2019-08-20 16:47:08 | Nabriva NBRV Gains FDA Approval for Pneumonia Drug Xenleta

2019-08-15 09:30:01 | Has Alexion Pharmaceuticals ALXN Outpaced Other Medical Stocks This Year?

2019-08-14 09:35:01 | Amgen AMGN Soars to 52-Week High, Time to Cash Out?

2019-08-14 08:34:12 | Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

2019-08-13 11:24:24 | Canadian drug price regulator may be flexible on rare diseases

2019-08-13 10:43:02 | Mergers & Acquisitions Take Center Stage in Biotech Industry

2019-08-13 09:40:01 | Can Value Investors Consider Alexion ALXN a Worthy Pick?